Oramed Pharmaceuticals Inc (ORMP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.68 (+0.21%), Market cap $0.19B, P/E ratio 3.09, 52-week low–high $2.06 ~ $4.73.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for Oramed Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Oramed Pharmaceuticals Inc trades at $4.68 (+0.21%). Real-time quotes and charts are available on BlackAll Trade.
Oramed Pharmaceuticals Inc has a market cap of about $0.19B. Its P/E ratio is 3.09.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral